105799-73-3

Usage

Uses

Used in Pharmaceutical Industry:
6-Fluoro-2,2-dimethylchroman-4-one is used as a key intermediate in the synthesis of pharmaceutical drugs due to its potential biological activities and structural properties that can be further modified to develop new therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, 6-Fluoro-2,2-dimethylchroman-4-one serves as an intermediate for the production of agrochemicals, leveraging its chemical properties to create compounds that can be used in pest control and crop protection.
Used in Organic Synthesis:
6-Fluoro-2,2-dimethylchroman-4-one is utilized as a building block in organic synthesis for the creation of a variety of pharmacologically active compounds, contributing to the development of new drugs and chemical entities with potential therapeutic applications.
Used in Research Applications:
6-Fluoro-2,2-dimethylchroman-4-one is also employed in research settings to explore its chemical properties, reactivity, and potential uses in the development of new chemical processes and understanding its role in biological systems.

Upstream product

• 394-32-1 1-(5-fluoro-2-hydroxyphenyl)ethan-1-one 
• 67-64-1 acetone 
• 371-41-5 4-Fluorophenol 
• 199334-92-4 4-N-ethylsulfonylamino-6-fluoro-2,2-dimethylchroman 
• 683-57-8 bromo-acetic acid amide 
• 405-51-6 4-fluorophenyl acetate 

Downstream Products

• 353235-70-8 2-(3-hydroxy-3-methyl)butyl-4-fluorophenol 
• 226923-00-8 3,4-dihydro-2,2-dimethyl-6-fluoro-4-(4-methylbenzenesulphonylaminocarbonylamino)-2H-1-benzopyran 
• 226923-01-9 4-(4-chlorobenzenesulphonylaminocarbonylamino)-3,4-dihydro-2,2-dimethyl-6-fluoro-2H-1-benzopyran 
• 226922-99-2 4-(benzenesulphonylaminocarbonylamino)-3,4-dihydro-2,2-dimethyl-6-fluoro-2H-1-benzopyran 
• 226922-93-6 4-amino-3,4-dihydro-2,2-dimethyl-6-fluoro-(2H)-1-benzopyran 

Relevant academic research and scientific papers

4,6-Disubstituted 2,2-dimethylchromans structurally related to the K ATP channel opener cromakalim: Design, synthesis, and effect on insulin release and vascular tone

Five series (ureas, thioureas, carbamates, sulfonylureas, and amides) of 4,6-disubstituted-2,2-dimethylchromans structurally related to cromakalim were prepared and evaluated, as putative ATP-sensitive potassium channel activators, on rat pancreatic islets and rat aorta rings. The biological data indicate that most compounds were, like the reference molecule cromakalim, more active on the vascular smooth muscle tissue (myorelaxant effect on 30 mM KCl induced contractions of rat aorta rings) than on the pancreatic tissue (inhibition of 16.7 mM glucose induced insulin release from rat pancreatic islets). However, some drugs (8h, 8i, 9f, 9g, 9h, and 9i) markedly inhibited insulin release and exhibited an activity equivalent or greater than that of diazoxide. Compounds 9h and 9i were also found to be more active on pancreatic β-cells than on vascular smooth muscle cells. Last, the amide 6b was selected in order to examine its mechanism of action on vascular smooth muscle cells. Pharmacological results suggest that the compound acted as a KATP channel opener. In conclusion, the present data indicate that appropriate structural modifications can generate dimethylchromans with pharmacological profiles different from that of cromakalim.

TRPV1 ANTAGONISTS

Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

TRPV1 ANTAGONISTS

Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Sulfonamide-substituted chromans, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them

Sulfonamide-substituted chromans, processes for their preparation, their use as a medicament or a diagnostic, and medicament comprising them Chromans of the formula I and of the formula 1a having the meanings R(A), R(B), R(C) and R(1) to R(8) indicated in the claims are outstandingly suitable for preparing a medicament for blocking the K+channel which is opened by cyclic adenosine monophosphate (cAMP); and further for preparing a medicament for inhibiting gastric acid secretion; for the treatment of ulcers of the stomach and of the intestinal region, in particular of the duodenum, for the treatment of reflux esophagitis, for the treatment of diarrheal illnesses, for the treatment and prevention of all types of arrhythmias including ventricular and supraventricular arrhythmias, and for the control of reentry arrhythmias and for the prevention of sudden heart death as a result of ventricular fibrillation.

Synthesis and activity of novel and selective Iks-channel blockers

Since the discovery of the IKs-potassium channel as the slowly activating component of the delayed rectifier current (Ik) in cardiac tissue, the search for blockers of this current has been intense. During the screening of KATP

Synthesis and pharmacological evaluation of K(ATP)-channel openers related to cromakalim: Introduction of arylsulphonylurea moieties

A series of 4-(arylsulphonylaminocarbonylamino)-3,4-dihydro-2,2-dimethyl-2 H-1-benzopyran derivatives were prepared and evaluated as potential ATP-sensitive potassium-channel activators. Pharmacological studies showed that some compounds expressed vasodilator efficacy on vascular smooth muscle. The compounds had no inhibitory activity on insulin secretion from pancreatic β-cells.

Sulfonamide-substituted chromans, processes for their preparation, their use as a medicament or diagnostic, and pharmaceutical preparations comprising them

Compounds of the formula I STR1 having the meanings of the substituents indicated in the claims are outstandingly efficacious substances for producing medicaments for the prophylaxis and for the therapy of cardiovascular disorders, in particular arrhythmias, for the treatment of ulcers of the gastrointestinal region or for the treatment of diarrheal disorders.

Hydantoin Bioisosteres. In Vivo Active Hydroxy Acetic Acid Aldose Reductase Inhibitors

The hypothesis that clinical side effects of the aldose reductase inhibitor (ARI) sorbinil were related to its hydantoin ring led to a bioisosteric analysis and replacement of the hydantoin by a spiro hydroxy acetic acid moiety as in 40.These hydroxy acids, compared to hydantoins, showed a similar potency increase on chroman 2-methyl substitution, a similar orthogonal relationship of acidic to aromatic moieties, and similar ARI enantioselectivity.In this series the six-membered spiro hydroxy acetic acid anion array is a bioisostere for a spiro hydantoin anion and leads to ARIs with excellent in vivo activity.In vitro and in vivo activity was improved over 40 by chroman cis 2-methylation as in 4 and by aromatic 6,7-halogen substitution.Compounds with the best acute in vivo activity in rats were compared for chronic in vivo activity.The highest tissue levels and best chronic in vivo activities were found in the racemic 6,7-dichloro and 6-fluoro-7-chloro analogues 18 and 23.ARI activity was enantioselective for 58 and 60, the 2R,4R-enantiomers of 18 and 23. 7-Chloro-6-fluoro-cis-4-hydroxy-2(R)-methyl-chroman-4-acetic acid (60) was selected for phase 1 clinical trials and did not exhibit sorbinil-like hypersensitivity side effects.